The FDA on April 21, 2014 approved CYRAMZA® for use as a single agent, for the treatment of patients with advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma, with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy. CYRAMZA® injection for intravenous infusion is a product of Eli Lilly and Company.
Bottom Ad
Advertisement
Subscribe
